A $6.3 million federal grant was recently awarded to Benjamin tenOever, PhD, to identify U.S. Food and Drug Administration-approved drugs that can be repurposed to prevent or treat COVID-19. Dr. tenOever’s lab is currently testing a group of 20 promising drugs that were narrowed down from thousands over the course of several months by teams led by Donald Ingber, MD, PhD, at the Wyss Institute for Biologically Inspired Engineering at Harvard University, and Matthew Frieman, PhD, at the University of Maryland School of Medicine. All three institutions are working together under a one-year $16 million umbrella grant from the U.S. Defense Advanced Research Projects Agency.